Advanced search

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

(2009) Leukemia. 24(3). p.521-535
Author
Organization
Abstract
Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols. Leukemia (2010) 24, 521-535; doi:10.1038/leu.2009.268; published online 24 December 2009
Keywords
minimal residual disease, ALL, MRD, flow cytometry, PCR, ACUTE LYMPHOBLASTIC-LEUKEMIA, MINIMAL-RESIDUAL-DISEASE, POLYMERASE-CHAIN-REACTION, TIME QUANTITATIVE PCR, PRECURSOR-B-ALL, ACUTE PROMYELOCYTIC LEUKEMIA, BONE-MARROW-TRANSPLANTATION, IG/TCR GENE REARRANGEMENTS, STEM-CELL TRANSPLANTATION, FLOW-CYTOMETRY, acute lymphoblastic leukemia

Citation

Please use this url to cite or link to this publication:

Chicago
Brüggemann, M, A Schrauder, T Raff, H Pfeifer, M Dworzak, OG Ottmann, V Asnafi, et al. 2009. “Standardized MRD Quantification in European ALL Trials: Proceedings of the Second International Symposium on MRD Assessment in Kiel, Germany, 18-20 September 2008.” Leukemia 24 (3): 521–535.
APA
Brüggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O., Asnafi, V., et al. (2009). Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia, 24(3), 521–535.
Vancouver
1.
Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann O, et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2009;24(3):521–35.
MLA
Brüggemann, M et al. “Standardized MRD Quantification in European ALL Trials: Proceedings of the Second International Symposium on MRD Assessment in Kiel, Germany, 18-20 September 2008.” Leukemia 24.3 (2009): 521–535. Print.
@article{884186,
  abstract     = {Assessment of minimal residual disease (MRD) has acquired a prominent position in European treatment protocols for patients with acute lymphoblastic leukemia (ALL), on the basis of its high prognostic value for predicting outcome and the possibilities for implementation of MRD diagnostics in treatment stratification. Therefore, there is an increasing need for standardization of methodologies and harmonization of terminology. For this purpose, a panel of representatives of all major European study groups on childhood and adult ALL and of international experts on PCR-and flow cytometry-based MRD assessment was built in the context of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. The panel summarized the current state of MRD diagnostics in ALL and developed recommendations on the minimal technical requirements that should be fulfilled before implementation of MRD diagnostics into clinical trials. Finally, a common terminology for a standard description of MRD response and monitoring was established defining the terms 'complete MRD response', 'MRD persistence' and 'MRD reappearance'. The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols. Leukemia (2010) 24, 521-535; doi:10.1038/leu.2009.268; published online 24 December 2009},
  author       = {Brüggemann, M and Schrauder, A and Raff, T and Pfeifer, H and Dworzak, M and Ottmann, OG and Asnafi, V and Baruchel, A and Bassan, R and Benoit, Yves and Biondi, A and Cavé, H and Dombret, H and Fielding, AK and Foà, R and Gökbuget, N and Goldstone, AH and Goulden, N and Henze, G and Hoelzer, D and Janka-Schaub, GE and Macintyre, EA and Pieters, R and Rambaldi, A and Ribera, JM  and Schmiegelow, K and Spinelli, O and Stary, J and von Stackelberg, A and Kneba, M and Schrappe, M and van Dongen, JJ},
  issn         = {0887-6924},
  journal      = {Leukemia},
  keywords     = {minimal residual disease,ALL,MRD,flow cytometry,PCR,ACUTE LYMPHOBLASTIC-LEUKEMIA,MINIMAL-RESIDUAL-DISEASE,POLYMERASE-CHAIN-REACTION,TIME QUANTITATIVE PCR,PRECURSOR-B-ALL,ACUTE PROMYELOCYTIC LEUKEMIA,BONE-MARROW-TRANSPLANTATION,IG/TCR GENE REARRANGEMENTS,STEM-CELL TRANSPLANTATION,FLOW-CYTOMETRY,acute lymphoblastic leukemia},
  language     = {eng},
  number       = {3},
  pages        = {521--535},
  title        = {Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008},
  volume       = {24},
  year         = {2009},
}

Web of Science
Times cited: